M
Max Levine
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 30
Citations - 1045
Max Levine is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 10, co-authored 20 publications receiving 320 citations. Previous affiliations of Max Levine include Worcester Polytechnic Institute & Kettering University.
Papers
More filters
Journal ArticleDOI
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton,Ryan Ptashkin,Teng Gao,Lior Z. Braunstein,Sean M. Devlin,Daniel Kelly,Minal Patel,Antonin Berthon,Aijazuddin Syed,Mariko Yabe,Catherine C. Coombs,Nicole M. Caltabellotta,Michael Walsh,Kenneth Offit,Zsofia K. Stadler,Diana Mandelker,Jessica Schulman,Akshar Patel,John Philip,Elsa Bernard,Gunes Gundem,Juan E. Arango Ossa,Max Levine,Juan S. Medina Martinez,Noushin Farnoud,Dominik Glodzik,Sonya Li,Mark E. Robson,Choonsik Lee,Paul D.P. Pharoah,Konrad H. Stopsack,Barbara Spitzer,Simon Mantha,James A. Fagin,Laura Boucai,Christopher J. Gibson,Benjamin L. Ebert,Andrew L. Young,Todd E. Druley,Koichi Takahashi,Nancy K. Gillis,Markus Ball,Eric Padron,David M. Hyman,David M. Hyman,José Baselga,Larry Norton,Larry Norton,Stuart Gardos,Stuart Gardos,Virginia M. Klimek,Virginia M. Klimek,Howard I. Scher,Howard I. Scher,Dean F. Bajorin,Dean F. Bajorin,Eder Paraiso,Ryma Benayed,Maria E. Arcila,Marc Ladanyi,David B. Solit,Michael F. Berger,Martin S. Tallman,Montserrat Garcia-Closas,Nilanjan Chatterjee,Luis A. Diaz,Ross L. Levine,Lindsay M. Morton,Ahmet Zehir,Elli Papaemmanuil +69 more
TL;DR: It is found mutations are selected differentially based on exposures, whereas cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA damage response genes (TP53, PPM1D, CHEK2).
Journal ArticleDOI
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard,Yasuhito Nannya,Robert P. Hasserjian,Sean M. Devlin,Heinz Tuechler,Juan S. Medina-Martinez,Tetsuichi Yoshizato,Yusuke Shiozawa,Ryunosuke Saiki,Luca Malcovati,Max Levine,Juan E. Arango,Yangyu Zhou,Francesc Solé,Catherine Cargo,Detlef Haase,Maria Creignou,Ulrich Germing,Yanming Zhang,Gunes Gundem,Araxe Sarian,Arjan A. van de Loosdrecht,Martin Jädersten,Magnus Tobiasson,Olivier Kosmider,Matilde Y. Follo,Felicitas Thol,Ronald Feitosa Pinheiro,Valeria Santini,Ioannis Kotsianidis,Jacqueline Boultwood,Fabio P.S. Santos,Julie Schanz,Senji Kasahara,Takayuki Ishikawa,Hisashi Tsurumi,Akifumi Takaori-Kondo,Toru Kiguchi,Chantana Polprasert,John M. Bennett,Virginia M. Klimek,Michael R. Savona,Monika Belickova,Christina Ganster,Laura Palomo,Guillermo Sanz,Lionel Ades,Matteo G. Della Porta,Alexandra Smith,Yesenia Werner,Minal Patel,Agnes Viale,Katelynd Vanness,Donna Neuberg,Kristen E. Stevenson,Kamal Menghrajani,Kelly L. Bolton,Pierre Fenaux,Andrea Pellagatti,Uwe Platzbecker,Michael Heuser,Peter Valent,Shigeru Chiba,Yasushi Miyazaki,Carlo Finelli,Maria Teresa Voso,Lee Yung Shih,Michaela Fontenay,Joop H. Jansen,José Cervera,Yoshiko Atsuta,Norbert Gattermann,Benjamin L. Ebert,Rafael Bejar,Peter L. Greenberg,Mario Cazzola,Eva Hellström-Lindberg,Seishi Ogawa,Elli Papaemmanuil +78 more
TL;DR: Clinical sequencing across a large prospective cohort of patients with myelodysplasic syndrome uncovers distinct associations between the mono- and biallelic states of TP53 and clinical presentation.
Journal ArticleDOI
Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
Teng Gao,Ryan Ptashkin,Kelly L. Bolton,Maria Sirenko,Christopher J. Fong,Barbara Spitzer,Kamal Menghrajani,Juan E. Arango Ossa,Yangyu Zhou,Elsa Bernard,Max Levine,Juan S. Medina Martinez,Yanming Zhang,Sebastià Franch-Expósito,Minal Patel,Lior Z. Braunstein,Daniel Kelly,Mariko Yabe,Ryma Benayed,Nicole M. Caltabellotta,John Philip,Ederlinda Paraiso,Simon Mantha,David B. Solit,Luis A. Diaz,Michael F. Berger,Virginia M. Klimek,Virginia M. Klimek,Ross L. Levine,Ahmet Zehir,Sean M. Devlin,Elli Papaemmanuil +31 more
TL;DR: In this article, the authors leverage peripheral blood sequencing data from 32,442 cancer patients to jointly characterize gene mutations and mosaic chromosomal alterations (mCAs) in clonal hematopoiesis (CH), a common state in cancer patients associated with a heightened risk of leukemia development.
Journal ArticleDOI
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
John Mascarenhas,Raajit K. Rampal,Heidi E. Kosiorek,Rupali Bhave,Elizabeth O. Hexner,Eunice S. Wang,Aaron T. Gerds,Camille N. Abboud,Marina Kremyanskaya,Dimitry Berenzon,Olatoyosi Odenike,Noushin Farnoud,Aishwarya Krishnan,Rona Singer Weinberg,Erin McGovern,Mohamed E. Salama,Vesna Najfeld,Juan S. Medina-Martinez,Juan E. Arango Ossa,Max Levine,Yangyu Zhou,Lonette Sandy,Mark L. Heaney,Ross L. Levine,Ruben A. Mesa,Amylou C. Dueck,Ronald Hoffman +26 more
TL;DR: The combination of decitabine and ruxolitinib was well tolerated, demonstrated favorable OS, and represents a therapeutic option for this high-risk patient population.
Journal ArticleDOI
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.
Wenbin Xiao,Maheetha Bharadwaj,Max Levine,Noushin Farnhoud,Friederike Pastore,Bartlomiej Getta,Anne Hultquist,Christopher Famulare,Juan Medina,Minal Patel,Qi Gao,Natasha Lewis,Janine D. Pichardo,Jeeyeon Baik,Brian C. Shaffer,Sergio Giralt,Raajit K. Rampal,Sean M. Devlin,Robert Cimera,Yanming Zhang,Maria E. Arcila,Elli Papaemmanuil,Ross L. Levine,Mikhail Roshal +23 more
TL;DR: The genetic aberrations that drive mixed phenotype acute leukemia (MPAL) remain largely unknown, with the exception of a small subset of MPALs harboring BCR-ABL1 and MLL translocations.